Qiagen stock gains on UBS upgrade and ECPI inclusion

Published on 09/13/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock drew support after MarketBeat said UBS upgraded it to Hold on September 12, 2026. Qiagen also reported fiscal 2025 EPS of USD 1.94 and free cash flow of USD 453.3 million.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) drew support on September 12, 2026, after ad hoc news reported that UBS Group upgraded the stock to Hold and that the average price target stood at USD 43.51. The same report said Berenberg kept a Hold view with a EUR 40.00 target on September 11, 2026.

Analyst targets stay tight

MarketBeat said on September 13, 2026 that Qiagen traded at USD 42.39 on September 11, 2026, with a market capitalization of USD 8.74 billion and volume of 1.11 million shares. The same data set put the consensus target at USD 43.51, only 2.6 percent above the close.

That narrow spread matters for investors because it leaves the stock close to the analyst average while still below the 52-week range high of USD 57.81 shown in the same MarketBeat snapshot.

Fiscal 2025 still anchors the story

Qiagen reported fiscal 2025 EPS of USD 1.94, up 424.3 percent year over year, and net income of USD 424.9 million, up 408.3 percent, according to StockTitan and StockTitan. Free cash flow reached USD 453.3 million in fiscal 2025, down 10.5 percent from the prior year, which gives the valuation debate a cash-flow anchor as well.

Index change adds context

STOXX said on September 12, 2026 that Qiagen will be added to the ECPI indices effective September 21, 2026. The stock's inclusion gives the name another dated market reference point alongside the analyst debate.

Stock level now

Qiagen stock stood at USD 42.39 on September 11, 2026, with a market capitalization of USD 8.74 billion and volume of 1.11 million shares. The shares were still below the consensus target of USD 43.51 and well under the 52-week high of USD 57.81.